Skip to content

Evaluating the effect of uterine artery embolization on fertility

Evaluating the effect of uterine artery embolization on fertility

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170925036388N2
Enrollment
60
Registered
2018-02-23
Start date
2017-06-22
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uterine fibroid. Leiomyoma of uterus, unspecified

Interventions

Intervention 1: Intervention group: Patients will be treated with uterine artery embolization. Then LH, FSH, Estradiol and CA-125(tumor marker) will be checked 6 months after surgery. Intervention 2:

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
No minimum to 40 Years

Inclusion criteria

Inclusion criteria: Smaller than 40 years old Intending to get pregnant Sonography explain myoma in uterine larger than 4cm in the largest diameter (biggest one larger than 4cm, for more than one myoma) Serum level of FSH lower than 30 IU/L in third day of period

Exclusion criteria

Exclusion criteria: Peduncular fibroid with thin pedicle that is smaller than 50% of fibroid apex. Fibroid bigger than uterine in 24 weeks of pregnancy Intracavity part of fibroid larger than 3cm Virgin patient want to get married (except patient with previous surgery)

Design outcomes

Primary

MeasureTime frame
LH, FSH and Estradiol(third day of period). Timepoint: Baseline and 6 months after surgery. Method of measurement: Blood sampling.;Sign of uterine fibroid questionnaire. Timepoint: Baseline and 6 months after surgery. Method of measurement: Questionnaire.;CBC. Timepoint: Baseline and 6 months after surgery. Method of measurement: Blood sampling.;Duration of returning to work. Timepoint: 6 months after surgery. Method of measurement: Asking the patient.;CRP. Timepoint: Baseline and 6 months after surgery. Method of measurement: Blood sampling.;CA-125(tumor marker). Timepoint: Baseline and 6 months after surgery. Method of measurement: Blood sampling.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alale Rajabzade Kanafi

Iran University of Medical Sciences

rajabzadeh.a@iums.ac.ir+98 21 6606 9049

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026